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Chemotherapy Plays a Major Role in the Inhibition of Catch-up
Growth During Maintenance Therapy for Childhood
Acute Lymphoblastic Leukemia
ƒ. J. Groot-Loonen, MD*; B. }. Otten, MD, PhD:):; M. A, van t' Hof, PhD§; R. J. J. Lippens, MD, PhD*; and
G. B. A. Stoelinga, MD, PhD:):
ABSTRACT. Objective. In children treated for acute 
lymphoblastic leukemia (ALL), catch-up growth occurs 
after cessation of therapy and not during maintenance 
therapy. In this study we investigated whether this inhi­
bition of catch-up growth during maintenance treatment 
is attributable to the influence of chemotherapy or to the 
influence of corticosteroids.
Patients. Forty-six children treated for ALL were in­
cluded in the study. In 27 patients maintenance therapy 
comprised vincristine (VCR), prednisone (Pred), or dexa- 
methasone (Dexa) alternated with 6-mercaptopurine (6- 
MP) and methotrexate (MTX) and 19 patients received 
maintenance therapy with 6-MP and MTX only. Treat­
ment did not include cranial irradiation.
Results, Statural growth during maintenance treat­
ment was comparable in both groups over the study 
period of 1,5 years.
Conclusion. Chemotherapy with 6-MP and MTX, and 
not corticosteroids, is the main factor that prevents 
catch-up growth from occurring during maintenance 
therapy for ALL. Pediatrics 1995;96:693-695; acute lym ­
phoblastic leukemia, corticosteroids, growth, maintenance  
chemotherapy.
ABBREVIATIONS. ALL, acute lymphoblastic leukemia; Cl, cra­
nial irradiation; VCR, vincristine; Dexa, dexamethasone; Pred, 
prednisone; L-asp, L-Asparaginase; MTX, methotrexate; 6-MP, 
6-mercaptopurine; ARA-C, cytosine-arabinoside; Zr score, relative 
standard deviation score.
Growth retardation during treatment for acute 
lymphoblastic leukemia (ALL) has been demon­
strated in many studies.1' 8 Diminished growth dur­
ing treatment could be caused by several factors 
including the disease itself, infections, and poor nu­
trition, but cranial irradiation (Cl), chemotherapy, 
and corticosteroids have been proposed as the main 
etiologic agents.2'3*5“8 The greatest part of the growth 
retardation occurred during the remission induction 
therapy, a phase of intensive chemotherapy. 
Catch-up growth did not occur before cessation of 
therapy.1,3"5,7,8 Maintenance therapy seemed not to 
affect growth to a great extent; however, mainte­
nance therapy did prevent a catch-up growth to oc-
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cur. Several authors assumed that this inhibition of 
catch-up growth is mainly due to the effect of ste­
roids.3,6,7 In this study we investigated the influence 
of corticosteroids on growth during maintenance 
therapy. We evaluated growth of children with ALL 
treated according to two different protocols: in the 
first protocol corticosteroids were a part of the main­
tenance therapy, in the second protocol maintenance 
therapy only comprised chemotherapy.
METHODS
Patients
Forty-six patients (19 girls and 27 boys) with ALL treated at the 
Department of Paediatric Oncology of the University of Nijmegen 
Hospital between 1984 and 1991 were included in the study. 
Patients with high-risk ALL, defined as leucocyte counts >50.000/ 
mm3 and/or mediastinal enlargement and patients with central 
nervous system involvement at time of diagnosis were excluded. 
To avoid the influence of pubertal growth spurt only children less 
than 10 years of age at diagnosis were included in the study. Age 
distribution was 1.6 to 9.9 years, median age, 5.1 years.
Treatment
Twenty-seven patients were treated with chemotherapy ac­
cording to protocol 6 of the Dutch Leukemia Working Group. 
Protocol 6 comprised: a) Induction treatment with vincristine 
(VCR), dexamethasone (Dexa) or prednisone (Pred) with L -aspar-  
aginase (L-Asp) and two doses of methotrexate (MTX) and pred­
nisone intrathecally; b) Central nervous system prophylaxis with 
high-dose MTX intravenously, and three doses MTX plus pred­
nisolone intrathecally; and c) Maintenance treatment with 2 weeks 
of VCR plus Pred or Dexa alternated with 5 weeks 6-mercapto­
purine (6-MP), 50 mg/m2 daily, plus MTX 30 m g/in2 once a week 
and 8 courses of MTX, prednisolone and cytosine-arabinoside 
(ARA-C) intrathecally.
Seventeen out of 27 patients treated according to protocol 6 
received Dexa, 6 mg/m2, during induction and maintenance treat­
ment and in 10 patients Dexa was replaced by Pred, 40 m g/m 2. 
The duration of induction treatment and central nervous system 
prophylaxis was 3 months, so maintenance therapy started 3 
months after diagnosis. Total duration of treatment was 2 years.
Nineteen patients were treated according to protocol 7 of the 
Dutch Leukemia Working Group. Protocol 7 comprised: a) Induc­
tion treatment with VCR, Pred, daunorubicin, L-asp, cyclophos­
phamide, ARA-C, and 6-MP and three doses MTX intrathecally; b) 
central nervous system prophylaxis with high-dose methotrexate 
(MTX) intravenously, 6-MP orally, and four doses of MTX intrath­
ecally; c) Reinduction treatment with VCR, Dexa, adriamycin, 
L-asp, cyclophosphamide, ARA-C and 6 thioguanine, and two 
doses of MTX intrathecally; and d) Maintenance treatment with 
6-MP, 50 m g/m 2 daily, and MTX, 20 m g/m 2 once a week. The 
maintenance treatment started 7 months after diagnosis. Total 
duration of treatment was 1.5 years. None of the patients in this 
study received cranial irradiation. In this study we investigated 
statural growth during 1.5 years of therapy.
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Measurements and Statistical Analysis
Patients' height and weight was measured by experienced staff* 
During the study period patients were measured 12 times per 
year. To standardize the results and to allow comparison of chil­
dren with different ages and sexes, values for height were trans­
formed into standard deviation scores using the Dutch reference 
values.9 Standard deviation score for height is defined as the 
difference between a patient's height and the age- and sex-appro- 
priate mean of the population divided by the corresponding stan­
dard deviation. Estimates of the standard deviation scores at 
regular time intervals (3 months) were obtained by interpolation 
of the individual standard deviation score curves. To measure the 
influence of therapy properly the relative standard deviation score 
(Zr score) was calculated, defined as: Zr = Zt — Z0 (Zt: standard 
deviation score at time point t after diagnosis, Z0: standard devi­
ation score at time of diagnosis).
Statistical comparison was made using the t test on the Zr 
scores. Zr scores are presented with ± the standard deviation.
RESULTS
The Zr scores for the height of each of the 27 
patients treated for ALL according to protocol 6 
(maintenance therapy comprising Pred or Dexa) 
compared with the Zr scores of 19 patients treated 
according to protocol 7 (maintenance treatment with­
out corticosteroids) are shown in the Figure. Height 
at diagnosis was not significantly different from the 
normal population. During treatment a decline in Zr 
score for height was shown in both groups. Three 
months after the start of therapy, the Zr score of 
patients treated according to protocol 6 was -0.2 ± 
0.2, The Zr score remained -0.2. The Zr score of 
patients treated according to protocol 7 was -0.3 ±
0.2 at 3 months and remained -0.3 during the whole 
treatment period. The differences between the two 
groups were not significant at any time (all P values 
> 10).
DISCUSSION
Growth retardation during treatment for ALL is of 
multifactorial etiology.5 Cl as central nervous system 
prophylaxis in the treatment for ALL has been im­
plicated as the main etiologic agent.8 Compared with
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Figure. Mean Zr score (±standard error) for height of patients 
treated for acute lymphoblastic leukemia (ALL) according to pro­
tocol 6 (maintenance therapy comprising prednisone or dexa­
methasone/ n = 27) (solid line) and according to protocol 7 (main­
tenance treatment without corticosteroids, n = 19) (broken line).
patients who were not irradiated, children who re­
ceived Cl showed more severe growth retardation 
and during the period of catch-up growth these pa­
tients did not fully regain the previous loss.3“5'7'8 Chil­
dren treated for ALL with chemotherapy and corti­
costeroids but without Cl also showed a diminished 
growth rate during treatment.4,7'8 Apart from im­
paired growth, retardation of bone age development 
nas also been reported during treatment for ALL.10 
Bone age retardation in patients who received Cl was 
the same as in patients who were not irradiated, 
suggesting a direct influence of chemotherapy 
and/or corticosteroids on skeletal maturation.10 The 
influence of chemotherapy alone on growth and 
bone age development is not known, but long-term 
corticosteroid therapy has been associated with 
growth inhibition and delayed skeletal matura­
tion.11,12 Short-term treatment with Pred in a dose of 
40 m g/m 2/day  and Dexa in a dose of 10 mg/m2/  
day, used during remission induction therapy for 
ALL have been shown to suppress growth hor­
mone secretion.13,14 This temporary inhibition of 
growth hormone secretion could contribute to the 
diminished growth during the early phase of ther­
apy. In this study both groups of patients showed 
loss of height standard deviation score during the 
initial phase of therapy. The question was whether 
patients who did not receive corticosteroids during 
maintenance treatment would show a different 
growth pattern compared with children who re­
ceived corticosteroids during the entire period of 
treatment. Although in protocol 6 corticosteroids 
were given intermittently (2 weeks on steroid 
treatment, 5 weeks off), this mode of treatment has 
also been associated with impaired growth.12 How­
ever, the growth pattern in both groups of patients 
during maintenance therapy proved to be the 
same; none of the patients showed catch-up 
growth. So we may conclude that corticosteroids 
were not the causal factor for inhibition of catch-up 
growth, but that this phenomena was mainly at­
tributable to chemotherapy with 6-MP and MTX. 
Treatment with MTX has been associated with en­
teropathy,15 which could result in malnutrition. 
For patients treated according to protocol 7 (with­
out corticosteroids during maintenance therapy) 
weight for height was not significantly different 
from the normal population; we conclude from 
this that malnutrition could not be a factor contrib­
uting to the inhibition of catch-up growth.
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NOTICE REGARDING THE AMERICAN ACADEMY OF PEDIATRICS
NUTRITION AWARD 1996
Nominations for the 1996 AAP Nutrition Award are now being solicited. 
Nominations must be in writing and should be limited to one per nominator. The 
letter should contain a description of the nominee's achievements and state clearly 
the basis for the recommendation (including references to the literature which 
describes his/her work). It is requested that the nominee's bibliography be sub­
mitted with the nominating letter, together with copies of available reprints. Letters 
supporting the nomination (no more than five) are to be solicited and screened by the 
nominator and forwarded to the attention of:
Edgar O. Ledbetter, MD, Director
Department of Maternal, Child and Adolescent Health
American Academy of Pediatrics
141 Northwest Point Boulevard
PO Box 927
Elk Grove Village, IL 60009-0927
Please note that the deadline for award nominations is December 14,1995.
The Academy appreciates your effort to assist in the appropriate selection of a 
deserving person for this award.
Nutrition Award Stipulations
The Nutrition Award of the American Academy of Pediatrics was established in 
1944. The award is made possible by a grant from the Infant Formula Council.
The Nutrition Award provides an honorarium of $3000 to be awarded under the 
following stipulations:
1. The award will be made for outstanding achievement in research relating to the 
nutrition of infants and children.
2. That the award be made fox research, which has been completed and publicly 
reported.
3. That the award be made for research, conducted by residents of the United 
States and Canada.
4. That the award be made to one individual or for one project.
5. The award is open to all regardless of age. No current member of the Committee 
on Nutrition shall be eligible for the award.
The Nutrition Award also includes round trip tourist class airfare as well as two 
days lodging at $150 per diem for the recipient and another person of h is/her 
choice to attend the Annual Meeting of the Academy.
The selection of the Award recipient is made by the Committee on Nutrition of 
the American Academy of Pediatrics, approved by the Board of Directors, and the 
award is presented at the Annual Meeting of the Academy.
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